Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis

CJ Black, NE Burr, M Camilleri, DL Earnest… - Gut, 2020 - gut.bmj.com
Objective Over half of patients with IBS have either diarrhoea (IBS-D) or a mixed stool
pattern (IBS-M). The relative efficacy of licenced pharmacological therapies is unclear in the …

[HTML][HTML] New insights into irritable bowel syndrome: from pathophysiology to treatment

A Hadjivasilis, C Tsioutis, A Michalinos… - Annals of …, 2019 - ncbi.nlm.nih.gov
Irritable bowel syndrome (IBS) is the most common reason to visit a gastroenterologist. IBS
was believed to be a functional disease, but many possible pathophysiologic mechanisms …

AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea

A Lembo, S Sultan, L Chang, JJ Heidelbaugh… - Gastroenterology, 2022 - Elsevier
Background & Aims Irritable bowel syndrome (IBS) is a common functional gastrointestinal
disorder associated with significant disease burden. This American Gastroenterological …

American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome

L Chang, A Lembo, S Sultan - Gastroenterology, 2014 - gastrojournal.org
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized
by abdominal pain and/or discomfort associated with altered defecation. 1 Other common …

Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions

DJ Cangemi, BE Lacy - Therapeutic advances in …, 2019 - journals.sagepub.com
Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) condition involving
numerous potential causative factors (eg alterations in gut microbiota, motility, brain–gut …

Current and future treatment approaches for IBS with diarrhoea (IBS‐D) and IBS mixed pattern (IBS‐M)

J Nee, A Lembo - Alimentary pharmacology & therapeutics, 2021 - Wiley Online Library
Background Irritable bowel syndrome‐diarrhoea (IBS‐D) and IBS‐mixed stool pattern (IBS‐
M) are disorders of gut‐brain interaction characterised by abdominal pain associated with …

Brain–gut axis: clinical implications

J Khlevner, Y Park, KG Margolis - Gastroenterology Clinics, 2018 - gastro.theclinics.com
The importance of the gastrointestinal (GI) tract in human disease was first raised by
Hippocrates m more than 2000 years ago. His statement, that “all disease begins in the gut,” …

Irritable Bowel Syndrome (Japanese Version)

S Sultan, A Malhotra - Annals of internal medicine, 2017 - acpjournals.org
1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a
metaanalysis. Clin Gastroenterol Hepatol. 2012; 10: 712-721. e4.[PMID: 22426087] 2 …

[HTML][HTML] Current US Food and Drug Administration-approved pharmacologic therapies for the treatment of irritable bowel syndrome with diarrhea

DM Brenner, GS Sayuk - Advances in therapy, 2020 - Springer
Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by abdominal
pain and alterations in stool form and/or frequency, leading to reduced quality of life …

[HTML][HTML] Pharmacologic agents for chronic diarrhea

KJ Lee - Intestinal research, 2015 - ncbi.nlm.nih.gov
Chronic diarrhea is usually associated with a number of non-infectious causes. When
definitive treatment is unavailable, symptomatic drug therapy is indicated. Pharmacologic …